J Pediatr Health Care. 2019 Nov-Dec;33(6):626-632. doi: 10.1016/j.pedhc.2019.03.002. Epub 2019 Jun 1.
This article discusses the controversial but promising topic of medical marijuana (MM) use in the pediatric population with epilepsy. Included is the importance of MM throughout history, the pharmacodynamics and pharmacokinetics, and a literature review that provides anecdotal evidence of the positive effect MM has on children suffering from seizures. From this literature review, dosage for treatment and management is provided. Also discussed is the recent FDA-approved pharmaceutical grade CBD product, Epidiolex, for treatment of two pediatric-onset seizure syndromes, Lennox-Gastaut and Dravet. Clinical implications regarding adverse side effects of MM use are also discussed. The aim of this article is to arm providers with contemporary knowledge on the risks and benefits of MM use in the pediatric population with epilepsy, which may boost their skills and confidence in educating and advocating for children with seizures. This novel, ever-changing medication is in the forefront of history and the news, making this topic especially important for review.
本文讨论了在患有癫痫的儿科人群中使用医用大麻（MM）这一颇具争议但前景广阔的话题。文中介绍了 MM 在历史上的重要性、药效学和药代动力学，以及对 MM 对癫痫患儿有积极影响的文献综述提供的轶事证据。从文献综述中，提供了治疗和管理的剂量。还讨论了最近获得 FDA 批准的药物级 CBD 产品 Epidiolex，用于治疗两种儿童发病的癫痫综合征，Lennox-Gastaut 和 Dravet。还讨论了 MM 使用的不良反应的临床意义。本文的目的是为提供者提供有关 MM 在患有癫痫的儿科人群中使用的风险和益处的最新知识，这可能会提高他们教育和倡导癫痫儿童的技能和信心。这种新颖的、不断变化的药物处于历史和新闻的前沿，因此特别重要。
